v3.26.1
Related parties (Tables)
12 Months Ended
Dec. 31, 2025
Related parties  
Summary of transactions with related party

December 31,

2025

  ​ ​ ​

2024

2023

(Euro, in thousands)

Trade and other receivables (1)

3,833

2,268

5,198

Trade and other payables

585

Year ended December 31,

2025

  ​ ​ ​

2024

2023

(Euro, in thousands)

Revenues recognized related to the performance obligation for the drug discovery platform

1,068,967

230,182

230,242

Revenues recognized related to the filgotinib performance obligation (2)

26,041

429,439

Royalty income related to the commercialization of filgotinib

12,177

10,604

9,466

Cost reimbursements related to the development of GLPG1690 (3)

128

299

Cross charges from and to Gilead relating to filgotinib (4)

36

3,643

Summary of remuneration package of the members of key management personnel

Year ended December 31,

  ​ ​ ​

2025

  ​ ​ ​

2024

  ​ ​ ​

2023

Remuneration of key management personnel:

Euro, in thousands (except for the number of subscription rights and RSUs)

Short-term benefits to executive Committee members as a group (1)

3,762

3,279

3,902

Board fees for members of the Board of Directors

791

859

749

Post-employment benefits (2)

216

186

209

Severance package (3)

1,520

3,150

Subscription rights granted in the year

Number of subscription rights granted in the year to Executive Committee members as a group

1,510,000

185,000

325,000

Total cost to be recognized for subscription rights granted in the year under IFRS 2

15,275

1,765

5,163

Number of RSUs granted in the year

Total number of RSUs granted in the year to Executive Committee members as a group (1)(4)

429,924

299,516

331,066